PTC Therapeutics, Inc.

361 articles with PTC Therapeutics, Inc.

• PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age

  6/7/2019

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Emflaza® (deflazacort) to expand its labeling to include patients with Duchenne muscular dystrophy who are between 2- and 5-years-old

• PTC Therapeutics Promotes Emily Hill to Chief Financial Officer

  6/3/2019

  PTC Therapeutics, Inc. today announced the promotion of Emily Hill to Chief Financial Officer.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 31, 2019

  5/31/2019

  PTC Therapeutics, Inc. announced that on May 20, 2019 it approved non-statutory stock options to purchase an aggregate of 76,250 shares of its common stock to 15 new employees.

• PTC Therapeutics to Participate at Upcoming Investor Conference - May 30, 2019

  5/30/2019

  PTC Therapeutics, Inc. announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, June 6th at 4:00 p.m. ET.

• PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders

  5/20/2019

  $545,000 awarded to help improve Duchenne muscular dystrophy diagnosis and screening across the globe

• PTC Therapeutics and MRI Interventions Announce Strategic Investment

  5/9/2019

  $4 million equity investment to advance delivery device R&D for CNS gene therapy portfolio and other company operations

• PTC Therapeutics to Participate at Upcoming Investor Conferences - May 8, 2019

  5/8/2019

  PTC Therapeutics, Inc. announced that management will present a company update at the following conferences

• Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients

  5/7/2019

  Babies with Type 1 SMA from Part 1 of FIREFISH continue to achieve motor milestones including standing

• 

  Playing Catch-up, Genentech's Oral Drug for SMA Shows Promise in Clinical Trials

  5/7/2019

  Genentech, a Roche company, presented data from its FIREFISH clinical trial of risdiplam in Type 1 spinal muscular atrophy (SMA) at the American Academy of Neurology Annual Meeting.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 3, 2019

  5/3/2019

  PTC Therapeutics, Inc. announced that on April 23, 2019 it approved non-statutory stock options to purchase an aggregate of 210,900 shares of its common stock to 27 new employees.

• PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update

  5/2/2019

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2019.

• Translarna™ (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy

  4/29/2019

  Ambulatory Duchenne patients who are 5 years and older with a nonsense mutation can now access a treatment that targets the underlying cause

• PTC Therapeutics to Host Conference Call to Discuss First Quarter 2019 Financial Results

  4/18/2019

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2019 financial results and provide an update on the company's business and outlook on Thursday, May 2, 2019 at 4:30 p.m. (ET) after closing of the market.

• PTC Therapeutics to Participate at Upcoming Investor Conferences - March 4, 2019

  3/4/2019

  PTC Therapeutics, Inc. announced that management will present a company update at the following conferences

• PTC to Expand Product Portfolio in Latin America with WAYLIVRA™

  3/4/2019

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive opinion for WAYLIVRA™ by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 1, 2019

  3/1/2019

  PTC Therapeutics, Inc. announced that on February 25, 2019 it approved non-statutory stock options to purchase an aggregate of 125,000 shares of its common stock to 20 new employees.

• PTC Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides a Corporate Update

  2/28/2019

  PTC Therapeutics, Inc. announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2018.

• PTC Therapeutics Announces Partial Exercise of Underwriter's Option to Purchase Additional Shares

  2/25/2019

  PTC Therapeutics, Inc. announced that the sole underwriter of its previously announced public offering of 6,720,000 shares of its common stock, which closed on January 25, 2019, has partially exercised its option to purchase additional shares of common stock at the public offering price less underwriting discounts and commissions.

• PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2018 Financial Results

  2/14/2019

  PTC Therapeutics, Inc. announced that the Company will host a webcast conference call to report its fourth quarter and year end 2018 financial results and provide an update on the company's business and outlook on Thursday, February 28, 2019 at 4:30 p.m. after closing of the market.

• PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy

  2/13/2019

  PTC Therapeutics, Inc. announced the launch of the fifth annual STRIVE grant award program for Duchenne Muscular Dystrophy.